<DOC>
	<DOCNO>NCT01258777</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics golimumab Japanese Caucasian Males .</brief_summary>
	<brief_title>A Study Pharmacokinetics Golimumab Japanese Caucasian Male Subjects</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( physician subject know assign study medication ) study assess safety , tolerability , immune response , pharmacokinetics ( body drug ) , golimumab ( Simponi ) . The study population consist 24 healthy male Japanese subject 24 healthy male Caucasian subject . Subjects receive single dose either 200 mg 400 mg golimumab placebo . Subjects study 16 week . Safety assessment perform throughout study include obtain evaluate laboratory test , vital sign ( eg , blood pressure ) , occurrence severity adverse event . A single dose 200 mg 400 mg golimumab , placebo .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Have clinically relevant abnormality nonsmoker agree smoke 10 cigarette 2 cigar per day throughout study Japanese subject bear Japan , outside Japan 5 year , Japanese parent maternal paternal grandparent , determine subject 's verbal report Japanese subject must valid Japanese passport Caucasian subject must Caucasian parent . Have history clinically significant , severe , progressive , uncontrolled renal , hepatic , hematological , gastrointestinal , endocrine , pulmonary , cardiac , neurologic , cerebral , psychiatric disease Have underlying physical psychological medical condition Be unable unwilling undergo multiple venipuncture poor tolerability lack easy access vein .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Healthy volunteer</keyword>
	<keyword>Japanese male</keyword>
	<keyword>Caucasian male</keyword>
	<keyword>Simponi</keyword>
</DOC>